ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Juno ends development of CAR-T therapy JCAR015 following patient deaths
March 03, 2017Juno Therapeutics said that it will end development of the experimental CAR-T therapy JCAR015 in adults with relapsed or refractory acute lymphoblastic leukaemia (ALL) following safety issues observed in a mid-stage trial. -
Kite Pharma reports positive six-month data for CAR-T therapy in non-Hodgkin lymphoma
March 01, 2017Kite Pharma on Tuesday reported positive six-month results from a mid-stage study investigating its experimental CAR-T therapy axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma.
Pharma Sources Insight January 2025
